MyFinsight
Home
Blog
About
Proceeds from sales and
maturities of investment...
$182,025K
(-65.69%↓ Y/Y)
Proceeds from exercise of
stock options and...
$8,925K
(-22.34%↓ Y/Y)
Net cash used in
investing activities
$26,293K
(154.77%↑ Y/Y)
Net cash provided by
financing activities
$8,925K
(-22.34%↓ Y/Y)
Canceled cashflow
$155,732K
Net change in cash,
cash equivalents and...
-$58,975K
(72.03%↑ Y/Y)
Canceled cashflow
$35,218K
Stock-based compensation
$24,881K
(-46.61%↓ Y/Y)
Accounts payable and
accrued expenses,...
$9,292K
(-16.74%↓ Y/Y)
Depreciation and
amortization
$1,073K
(-43.05%↓ Y/Y)
Noncash lease expense
$683K
(-57.45%↓ Y/Y)
Deferred revenue
$516K
(-47.56%↓ Y/Y)
Purchases of investment
securities
$155,211K
(-72.96%↓ Y/Y)
Purchases of property and
equipment
$521K
(-88.27%↓ Y/Y)
Net cash used in
operating activities
-$94,193K
(45.96%↑ Y/Y)
Canceled cashflow
$36,445K
Net loss
-$120,855K
(43.10%↑ Y/Y)
Trade accounts
receivable
$6,274K
Accretion of purchase
discounts and...
$2,023K
(-77.74%↓ Y/Y)
Operating lease
liabilities
-$665K
(62.77%↑ Y/Y)
Prepaid expenses and
other assets
$463K
(-95.91%↓ Y/Y)
Inventory
$358K
Back
Back
Cash Flow
Crinetics Pharmaceuticals, Inc. (CRNX)
Crinetics Pharmaceuticals, Inc. (CRNX)
source: myfinsight.com